HH78 was shown to displace the fluorescent SMO antagonist BODIPY-cyclopamine using U2OS cells overexpressing human SMO and to overcome vismodegib resistance in chronic myeloid leukemia cells [117]. Here, SMO is linked to chronic myelogenous leukemia, BCR-ABL1 positive.